JP2018538307A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538307A5
JP2018538307A5 JP2018532035A JP2018532035A JP2018538307A5 JP 2018538307 A5 JP2018538307 A5 JP 2018538307A5 JP 2018532035 A JP2018532035 A JP 2018532035A JP 2018532035 A JP2018532035 A JP 2018532035A JP 2018538307 A5 JP2018538307 A5 JP 2018538307A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
lymphoma
fibrosis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532035A
Other languages
English (en)
Japanese (ja)
Other versions
JP6731483B2 (ja
JP2018538307A (ja
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed filed Critical
Priority claimed from PCT/GB2016/053968 external-priority patent/WO2017103611A1/en
Publication of JP2018538307A publication Critical patent/JP2018538307A/ja
Publication of JP2018538307A5 publication Critical patent/JP2018538307A5/ja
Application granted granted Critical
Publication of JP6731483B2 publication Critical patent/JP6731483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532035A 2015-12-16 2016-12-16 キナーゼ阻害剤として有用な化合物 Active JP6731483B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GB1522245.8 2015-12-16
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
GB1613945.3 2016-08-15
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116636A Division JP7086140B2 (ja) 2015-12-16 2020-07-06 キナーゼ阻害剤として有用な化合物

Publications (3)

Publication Number Publication Date
JP2018538307A JP2018538307A (ja) 2018-12-27
JP2018538307A5 true JP2018538307A5 (enExample) 2020-06-18
JP6731483B2 JP6731483B2 (ja) 2020-07-29

Family

ID=57590725

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018532035A Active JP6731483B2 (ja) 2015-12-16 2016-12-16 キナーゼ阻害剤として有用な化合物
JP2020116636A Active JP7086140B2 (ja) 2015-12-16 2020-07-06 キナーゼ阻害剤として有用な化合物
JP2022092275A Active JP7419437B2 (ja) 2015-12-16 2022-06-07 キナーゼ阻害剤として有用な化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020116636A Active JP7086140B2 (ja) 2015-12-16 2020-07-06 キナーゼ阻害剤として有用な化合物
JP2022092275A Active JP7419437B2 (ja) 2015-12-16 2022-06-07 キナーゼ阻害剤として有用な化合物

Country Status (38)

Country Link
US (8) US10695323B2 (enExample)
EP (2) EP3390395B1 (enExample)
JP (3) JP6731483B2 (enExample)
KR (2) KR20210018530A (enExample)
CN (9) CN113603645B (enExample)
AU (4) AU2016373530B2 (enExample)
CA (1) CA3008488C (enExample)
CL (1) CL2018001591A1 (enExample)
CO (1) CO2018006164A2 (enExample)
CR (1) CR20180367A (enExample)
CY (2) CY1123561T1 (enExample)
DK (1) DK3390395T3 (enExample)
EA (1) EA035132B1 (enExample)
ES (2) ES2828431T3 (enExample)
FI (1) FIC20240004I1 (enExample)
FR (1) FR24C1009I2 (enExample)
HR (1) HRP20201835T1 (enExample)
HU (2) HUE051921T2 (enExample)
IL (4) IL285976B2 (enExample)
LT (2) LT3390395T (enExample)
LU (1) LUC00330I2 (enExample)
MA (2) MA49809A1 (enExample)
MD (1) MD3390395T2 (enExample)
MX (2) MX394193B (enExample)
MY (2) MY202026A (enExample)
NL (1) NL301262I2 (enExample)
NO (1) NO2024008I1 (enExample)
NZ (1) NZ743553A (enExample)
PE (3) PE20220502A1 (enExample)
PH (1) PH12018501268A1 (enExample)
PT (1) PT3390395T (enExample)
RS (1) RS60982B9 (enExample)
SG (2) SG11201805044WA (enExample)
SI (1) SI3390395T1 (enExample)
TN (1) TN2018000213A1 (enExample)
UA (2) UA127863C2 (enExample)
WO (1) WO2017103611A1 (enExample)
ZA (4) ZA201804137B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
UA127863C2 (uk) 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
KR20210028144A (ko) * 2018-04-06 2021-03-11 블랙 벨트 티엑스 리미티드 Atf6 저해제 및 그의 용도
WO2019220962A1 (ja) * 2018-05-18 2019-11-21 富士フイルム株式会社 3-ジフルオロメチルピラゾール化合物の製造方法及び3-ジフルオロメチルピラゾール-4-カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー, インコーポレイテッド (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
US20220273593A1 (en) * 2019-09-19 2022-09-01 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
MX2022006631A (es) * 2019-12-06 2022-09-07 Loxo Oncology Inc Dosificacion de un inhibidor de la tirosina cinasa de bruton.
US20230122807A1 (en) 2020-01-02 2023-04-20 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Btk inhibitors
JP2023518006A (ja) * 2020-03-12 2023-04-27 フォチョン・バイオサイエンシーズ・リミテッド キナーゼ阻害剤としての化合物
TWI809489B (zh) 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
BR112023021235A2 (pt) * 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
IL309427A (en) * 2021-07-01 2024-02-01 Hangzhou Healzen Therapeutics Co Ltd TYROSINE KINASE AND MUTANT DEGRADER, Broughton's composition and application
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
US20250074911A1 (en) 2021-12-14 2025-03-06 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
WO2023165570A1 (zh) * 2022-03-03 2023-09-07 深圳市塔吉瑞生物医药有限公司 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
EP4493557A4 (en) * 2022-03-18 2026-03-18 Insilico Medicine Ip Ltd PYRAZOLE MEMBRANE-ASSOCIATED CDC2-SPECIFIC TYROSINE AND THREONINE KINASE INHIBITORS (PKMYT1) AND THEIR USES
CN115894376B (zh) * 2022-12-15 2025-05-16 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途
IL322630A (en) 2023-02-22 2025-10-01 Assia Chem Ind Ltd Solid forms of pirobrutinib
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
KR20250046558A (ko) 2023-09-27 2025-04-03 임창섭 5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
WO2025124496A1 (zh) * 2023-12-13 2025-06-19 正大天晴药业集团股份有限公司 含有吡唑环和双环杂芳基的化合物、其药物组合物及用途
WO2025137329A1 (en) * 2023-12-22 2025-06-26 Neupharma, Inc Certain chemical entities, compositions, and methods
CN119059973A (zh) * 2024-08-12 2024-12-03 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的合成工艺
CN119059974B (zh) * 2024-08-12 2025-10-28 武汉九州钰民医药科技有限公司 一种吡托布鲁替尼的制备方法
CN120504661B (zh) * 2025-07-14 2025-11-07 复旦大学 Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148718A0 (en) 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CN101553224A (zh) * 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
AU2009273197B2 (en) * 2008-07-24 2014-01-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EA026692B1 (ru) * 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
US8962831B2 (en) 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
PL2710007T3 (pl) 2011-05-17 2020-06-01 The Regents Of The University Of California Inhibitory kinazy
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK2861599T3 (da) 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
JP6348492B2 (ja) * 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ(btk)阻害剤としてのヘテロ芳香族化合物
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
BR112015009624A2 (pt) * 2012-11-02 2017-11-14 Pfizer inibidores de tirosina cinase de bruton
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
CN104341388B (zh) * 2013-10-16 2017-03-22 北京诺诚健华医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
KR20160117614A (ko) 2014-02-21 2016-10-10 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
EA032530B1 (ru) 2015-01-28 2019-06-28 Байер Фарма Акциенгезельшафт 4h-пирроло[3,2-c]пиридин-4-оновые производные
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
AU2016369505B2 (en) 2015-12-16 2019-08-15 Ecolab Usa Inc. Peroxyformic acid compositions for membrane filtration cleaning
CN108368086B (zh) 2015-12-16 2021-01-08 勃林格殷格翰国际有限公司 可用于治疗自身免疫疾病的二吡唑基衍生物
US10981858B2 (en) 2015-12-16 2021-04-20 Priostar Pty Ltd Dendrimer and formulations thereof
UA127863C2 (uk) * 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази

Similar Documents

Publication Publication Date Title
JP2018538307A5 (enExample)
HRP20201835T1 (hr) Spojevi korisni kao inhibitori kinaze
JP2020172535A5 (enExample)
WO2021249057A1 (zh) 杂环化合物及其用途
US10800792B2 (en) Inhibitors of Bruton's tyrosine kinase and method of their use
US9567339B2 (en) Primary carboxamides as BTK inhibitors
ES2655971T9 (es) Compuestos de aminopirimidinilo como inhibidores de JAK
SI2892900T1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
WO2010131146A1 (en) Cyclobutenedione derivatives
JP2016534146A5 (enExample)
CN106459045A (zh) 杂环激酶抑制剂
JP2015527401A5 (enExample)
CN109071546A (zh) 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
JP2018534326A5 (enExample)
JP2018536686A (ja) ブルトン型チロシンキナーゼの阻害剤としての多環式化合物
JP2018515531A5 (enExample)
JP2024508794A (ja) Tyk2阻害剤およびその使用
US20150361100A1 (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
JP2024519088A (ja) ピペラジン誘導体及びその医薬における使用
JP2023538304A (ja) 化合物、組成物及び方法
CN107344940A (zh) Btk抑制剂及其用途
WO2015151006A1 (en) Substituted purine compounds as btk inhibitors
SG11202113167QA (en) Fused heterocyclic derivatives
US20230416205A1 (en) Compounds, compositions, and methods
TW201247657A (en) Isoxazolines as therapeutic agents